When President Trump signed executive orders on the first day of his second term calling for a 90-day review of all foreign assistance, most Americans — including Medicare beneficiaries — may not have immediately connected that decision to their own health. But the subsequent freeze on payments to the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the broader dismantling of USAID, has set off a chain of consequences that reaches closer to home than many seniors realize. Understanding what the Global Fund does, what U.S. withdrawal means, and how it intersects with Medicare coverage for infectious diseases is not just a matter of foreign policy — it is a matter of public health literacy for anyone over 65.
The Global Fund was established in 2002 as an independent, public-private multilateral financing body with a singular mission: pool money from donor governments and private sources to fight HIV/AIDS, tuberculosis, and malaria in more than 100 low- and middle-income countries. It is not a small operation. The Global Fund invests up to $5 billion per year in these programs. Since its founding, it reports having helped save 70 million lives and reduce the combined death rate from its three target diseases by 63%. In 2024 alone, 25.6 million people were receiving antiretroviral therapy with Global Fund support, 7.4 million people were treated for tuberculosis, and 162 million insecticide-treated mosquito nets were distributed to prevent malaria deaths. These are not abstract statistics — they represent the infrastructure of global infectious disease control that indirectly protects every American, including Medicare beneficiaries.
The United States was not just a participant in the Global Fund — it was the architect. The U.S. government was instrumental in creating the organization and has historically been its largest single donor, accounting for approximately 33% of total funding. The U.S. also holds one of twenty seats on the Global Fund's Board of Directors and sits on two Board committees, giving it significant governance and oversight authority. When the Trump administration issued a stop-work order that froze all payments and services for work already underway, it did not simply pause a line item in a foreign budget — it pulled the structural cornerstone from an organization that dozens of countries depend on for their entire national HIV, TB, and malaria response.
A waiver was issued to allow what the administration described as life-saving humanitarian assistance to continue, but program implementers on the ground reported that the waiver was narrowly defined and difficult to obtain in practice. As a result, many programs were disrupted and some were ended entirely. Responsibility for remaining global health programs has since been transferred from the now-dissolved USAID to the State Department, a transition that health policy experts note introduces significant administrative uncertainty. Several legal challenges have been filed against these executive actions, but as of August 2026, meaningful legal remedy has been limited.
So why does any of this matter to a 70-year-old Medicare beneficiary in, say, Phoenix or Pittsburgh? The answer operates on several levels. First, infectious diseases do not respect national borders. Tuberculosis, in particular, is a disease that the U.S. has not eliminated domestically. According to the CDC, the U.S. recorded over 9,600 TB cases in 2023, and a significant proportion involve foreign-born individuals or people who have traveled internationally. When global TB treatment infrastructure collapses — as it may in countries that relied almost entirely on Global Fund financing — drug-resistant strains become more prevalent and more likely to travel. Seniors, whose immune systems are typically less robust than those of younger adults, are among the most vulnerable to TB exposure and complications.
Second, for Medicare beneficiaries who are themselves living with HIV — a population that has grown substantially as antiretroviral therapy has extended life expectancy — the domestic policy environment surrounding HIV funding is directly relevant. Changes to the Department of Health and Human Services, including proposed cuts and organizational restructuring that have accompanied the broader foreign aid review, are likely to affect domestic HIV programs as well. The Ryan White HIV/AIDS Program, which provides care and medications to low-income Americans living with HIV who are not fully covered by other insurance, operates under HHS. Medicare Part D covers antiretroviral medications, but Ryan White often fills the gaps in cost-sharing that Part D does not cover. If HHS reorganization reduces Ryan White funding, Medicare beneficiaries living with HIV may face higher out-of-pocket costs for the medications that keep them alive.
Data Snapshot: According to CMS.gov data, Medicare Part D covered approximately 1.6 million beneficiaries with HIV-related diagnoses in recent enrollment years, with antiretroviral drugs among the highest-cost specialty tier medications in Part D formularies. The average Medicare Part D enrollee paid a base beneficiary premium of $36.78 per month in 2025, but beneficiaries on specialty HIV medications often face cost-sharing that can reach the catastrophic coverage threshold — now capped at $2,000 in out-of-pocket costs annually under the Inflation Reduction Act's 2025 provisions — far earlier in the year than the average enrollee.
Third, seniors who travel internationally — a group that includes millions of Medicare beneficiaries who winter abroad, visit family in other countries, or take international cruises — face a changed risk landscape when global disease control programs are weakened. Malaria, for instance, is not a disease most American seniors think about, but it is a serious and potentially fatal illness for older adults with compromised immune function. The 162 million mosquito nets distributed by the Global Fund in 2024 represent a form of disease suppression that benefits travelers as much as local populations. Fewer nets, less vector control, and reduced treatment access in endemic regions means higher transmission rates — and higher risk for visiting seniors whose Medicare coverage does not extend outside U.S. borders.
On that last point, it is worth being explicit: Original Medicare — Parts A and B — does not cover medical care received outside the United States, with very limited exceptions involving Canadian or Mexican border emergencies. If you are a Medicare beneficiary who travels internationally and you contract malaria, TB, or another infectious disease abroad, your Medicare will not pay for treatment received in that country. Some Medicare Advantage plans in 2025 and 2026 have included limited emergency international coverage as a supplemental benefit, and Medigap Plans C, D, F, G, M, and N include foreign travel emergency coverage up to $50,000 lifetime (after a $250 deductible and 20% coinsurance) for emergencies in the first 60 days of a trip. If you travel internationally and do not have one of these Medigap plans or a Medicare Advantage plan with international emergency benefits, you are financially exposed.
For seniors who want to understand how the Global Fund disruption fits into the broader Medicare and domestic health policy picture, the most important thing to track is what happens to HHS funding and structure over the next 12 to 24 months. The proposed reorganization of HHS — which oversees Medicare, Medicaid, the CDC, NIH, and the Ryan White program — could affect everything from how Medicare Advantage plans are regulated to how domestic infectious disease surveillance is funded. The Centers for Medicare and Medicaid Services (CMS) administers Medicare and publishes detailed data on plan availability, premiums, and enrollment at CMS.gov. Beneficiaries can review their current plan options and compare alternatives at Medicare.gov or by calling 1-800-MEDICARE.
If you are currently enrolled in a Medicare Advantage plan and concerned about how your HIV medications, TB treatments, or other infectious disease-related prescriptions are covered, the most actionable step is to review your plan's formulary — the official list of covered drugs — before the next Annual Enrollment Period, which runs October 15 through December 7 each year. During AEP, you can switch Medicare Advantage plans or return to Original Medicare without penalty. If you miss AEP, the Open Enrollment Period from January 1 through March 31 allows you to switch from one Medicare Advantage plan to another, or to drop Medicare Advantage and return to Original Medicare. Outside these windows, switching typically requires a Special Enrollment Period triggered by a qualifying life event such as moving, losing other coverage, or a plan leaving your service area.
For beneficiaries living with HIV specifically, it is worth knowing that Medicare's Extra Help program — also called the Low Income Subsidy — can significantly reduce Part D premiums and cost-sharing for antiretroviral medications. In 2025, full Extra Help eligibility is available to individuals with incomes up to 135% of the federal poverty level and limited assets. Partial Extra Help extends to 150% of the federal poverty level. Applications are accepted year-round through the Social Security Administration at SSA.gov. Given the potential for Ryan White program funding to be affected by HHS restructuring, ensuring you are enrolled in every Medicare subsidy program you qualify for is a practical hedge against future cost increases.
The broader lesson from the Global Fund situation is one that Medicare beneficiaries are well-positioned to understand: health systems are interconnected, and funding decisions made at the policy level — whether in Washington or in Geneva — eventually show up in individual medical bills, drug formularies, and disease exposure risks. The U.S. built the Global Fund because American policymakers in 2002 understood that controlling AIDS, TB, and malaria abroad was also a matter of protecting Americans at home. Whether that logic continues to guide policy in 2026 and beyond remains an open question, and one that seniors — who vote in higher numbers than any other age group — are right to be paying attention to.